Isoray - ISR Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Isoray in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ISR shares.
View ISR analyst ratings or view top-rated stocks.

1 analysts have issued 12 month target prices for Isoray's shares. Their ISR share price forecasts range from $1.25 to $1.25. On average, they expect the company's stock price to reach $1.25 in the next twelve months. This suggests a possible upside of 253.3% from the stock's current price.
View analysts price targets for ISR or view top-rated stocks among Wall Street analysts.

Isoray's stock was trading at $0.38 at the start of the year. Since then, ISR stock has decreased by 6.9% and is now trading at $0.3538.
View the best growth stocks for 2022 here.

Isoray is scheduled to release its next quarterly earnings announcement on Monday, September 19th 2022.
View our ISR earnings forecast.

Isoray, Inc. (NYSEAMERICAN:ISR) issued its quarterly earnings results on Wednesday, November, 10th. The healthcare company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.01. The healthcare company had revenue of $2.56 million for the quarter, compared to analyst estimates of $2.58 million. Isoray had a negative net margin of 48.05% and a negative trailing twelve-month return on equity of 9.19%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Isoray investors own include Brainstorm Cell Therapeutics (BCLI), OPKO Health (OPK), Bausch Health Companies (BHC), Anavex Life Sciences (AVXL), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MannKind (MNKD), CTI BioPharma (CTIC), Idera Pharmaceuticals (IDRA) and Palatin Technologies (PTN).

Isoray trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

Isoray's stock is owned by a variety of retail and institutional investors. Top institutional investors include Perkins Capital Management Inc. (2.05%) and Taylor & Morgan Wealth Management LLC (0.55%). Insiders that own company stock include Jonathan Robert Hunt, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale and William Cavanagh.
View institutional ownership trends.

Shares of ISR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ISR stock can currently be purchased for approximately $0.35.

Isoray (NYSEAMERICAN:ISR) has a market capitalization of $50.25 million and generates $10.05 million in revenue each year. The healthcare company earns $-3,390,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.

Isoray employs 61 workers across the globe.

Isoray's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The official website for the company is isoray.com. The healthcare company can be reached via phone at (509) 375-1202, via email at dbabcock@isoray.com, or via fax at 509-267-3670.